Philippines Business News API

{
    "totalArticles": 286454,
    "articles": [
        {
            "id": "84f2e6d26c5a5846543351f9c5e6677e",
            "title": "BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer",
            "description": "Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated portfolio spanning immunomodulators, antibody-drug conjugates, mRNA cancer immunotherapies, and their combinationsData updates for pumitamig, a PD-L1xVEGF-A bispecific immunomodulator, from three clinical trials conducted in China further strengthen the evidence supporting its previously observed efficacy and safety profile in lung cancerResults of stage 1 from the global Phase 3 PRESERVE-003 clinical trial of gotistobart showed clinically meaningful survival outcomes and antitumor activity compared to the current standard of care in second-line or later therapy of squamous non-small cell lung cancer MAINZ, Germany, March 24, 2026 - BioNTech SE (Nasdaq: BNTX, 'BioNTech” or 'the Company”) will present data from its diversified portfolio in the field of lung cancer at the European Lung Cancer Congress ('ELCC”) held in Copenhagen, Denmark, from March 25-28, 2026. The data updates covered in both oral and poster presentations highlight progress across late-stage immunomodulator candidates pumitamig and gotistobart, as well as antibody-drug conjugate ('ADC”) programs, across various lung cancer subtypes and lines of treatment. BioNTech’s clinical portfolio encompasses both monotherapies and combinations with standard of care treatments, as well as novel-novel combination regimens aimed at delivering differentiated therapeutic profiles for the treatment of patients with lung cancer across all stages of the disease.",
            "content": "Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated portfolio spanning immunomodulators, antibody-drug conjugates, mRNA cancer immunotherapies, and their combination... [14197 chars]",
            "url": "https://www.manilatimes.net/2026/03/24/tmt-newswire/globenewswire/biontech-clinical-data-at-elcc-2026-highlight-potential-of-differentiated-late-stage-portfolio-in-lung-cancer/2306227",
            "image": "https://www.manilatimes.net/manilatimes/uploads/images/2026/03/24/985565.png",
            "publishedAt": "2026-03-24T10:55:35Z",
            "lang": "en",
            "source": {
                "id": "e3ad8bbf7dbe3c3defc56a8393455066",
                "name": "The Manila Times",
                "url": "https://www.manilatimes.net"
            }
        },
        {
            "id": "861e0813434ba8aea3a4a1e8e4ae9fdb",
            "title": "Philippine president says grounding planes due fuel shortage a ‘distinct possibility’",
            "description": "Philippine President warns of potential plane groundings due to jet fuel shortages linked to the U.S.-Israeli conflict.",
            "content": "The Philippines said grounding planes ​due to a ‌shortage of jet fuel ​brought on ⁠by the U.S.-Israeli war with Iran is a \"distinct ‌possibility\", Bloomberg News reported on Tuesday, ‌citing an interview ‌with ⁠the South East Asian ⁠country's preside... [572 chars]",
            "url": "https://www.thehindubusinessline.com/news/world/philippine-president-says-grounding-planes-due-fuel-shortage-a-distinct-possibility/article70778480.ece",
            "image": "https://bl-i.thgim.com/public/incoming/rchg91/article70778506.ece/alternates/LANDSCAPE_1200/2026-03-10T162211Z_186131303_RC2Q1KACT8KK_RTRMADP_3_UN-PHILIPPINES-MARCOS.JPG",
            "publishedAt": "2026-03-24T06:18:15Z",
            "lang": "en",
            "source": {
                "id": "03ed91e3e8b621f81a84ed04f779afec",
                "name": "BusinessLine",
                "url": "https://www.thehindubusinessline.com"
            }
        },
        {
            "id": "f093fbe98bc6e5e1f00da434388f7b41",
            "title": "Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid",
            "description": "Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid",
            "content": "Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid\nApproval in moderate-to-severe patients was based on pivotal study results showing over four times more Dupixent patients experie... [18788 chars]",
            "url": "https://www.manilatimes.net/2026/03/24/tmt-newswire/globenewswire/press-release-sanofi-and-regenerons-dupixent-approved-in-japan-as-the-first-targeted-medicine-to-treat-adults-with-bullous-pemphigoid/2306068",
            "image": "https://www.manilatimes.net/manilatimes/uploads/images/2026/03/24/985225.jpg",
            "publishedAt": "2026-03-24T06:12:24Z",
            "lang": "en",
            "source": {
                "id": "e3ad8bbf7dbe3c3defc56a8393455066",
                "name": "The Manila Times",
                "url": "https://www.manilatimes.net"
            }
        }
    ]
}